Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Bodies Agree Clearer Rules On Joint Procurement Of Vaccines & Treatments

Executive Summary

The new regulation on cross-border threats to health is the final part of the European Health Union, along with strengthened roles for the European Medicines Agency and the European Centre for Disease Prevention and Control. Its aim is to ensure collective EU action on preparedness, surveillance, risk assessment, and early warning and response in the event of health emergencies.

You may also be interested in...



New EU Rules Imminent On Joint Procurement Of Vaccines & Drugs In Health Crises

EU legislation just approved by legislators will require the European Commission to provide information on prices, manufacturers, delivery time frames and joint procurement processes for vaccines and medicines used in tackling future health crises such as pandemics.

Coronavirus Notebook: UK OKs Second Bivalent Vaccine, European Companies Warn On Joint Vaccine Procurement Plans

The Swiss medicines regulator has approved the bivalent version of Spikevax and given the green light to use of the Novavax COVID-19 vaccine in younger people.

EU Committee To Discuss Future COVID-19 Vaccine Purchasing Deals

The health commissioner and three member state health ministers will take part in a debate on how advance purchase agreements were drawn up during the pandemic, and how they should be handled in future health crises.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel